ES2098357T3 - Derivado de indol. - Google Patents

Derivado de indol.

Info

Publication number
ES2098357T3
ES2098357T3 ES91911488T ES91911488T ES2098357T3 ES 2098357 T3 ES2098357 T3 ES 2098357T3 ES 91911488 T ES91911488 T ES 91911488T ES 91911488 T ES91911488 T ES 91911488T ES 2098357 T3 ES2098357 T3 ES 2098357T3
Authority
ES
Spain
Prior art keywords
alkyl
group
carbonyl
carbon atoms
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91911488T
Other languages
English (en)
Inventor
Hiroshi Nagase
Akira Mizusuna
Yoshihiro Onoda
Koji Kawai
Shu Matsumoto
Takashi Endo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2098357T3 publication Critical patent/ES2098357T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un procedimiento para preparar un derivado de indol representado por la **fórmula** en la cual R1 es un grupo alquilo C1-5, cicloalquil C4-7-alquilo, cicloalquenil C5-7-alquilo, aralquilo C7-14, trans-alquenilo C4-5, alilo, furanil-2-il-alquilo C1-5, tienil-2-il-alquilo C1-5, viniloxicarbonilo, tricloro-etoxicarbonilo, benciloxicarbonilo, alcanólo que tiene hasta 5 átomos de carbono, aralquil C7-14-carbonilo, 2-furólo, tiofeno-2-carbonilo, cicloalquil C4-7-carbonilo, alquenil C3-8-carbonilo, o anisólo,R2 es un átomo de hidrógeno o un grupo alquilo C1-3, bencilo o alcanólo que tiene hasta 5 átomos de carbono, R3 es un átomo de hidrógeno, fluor,cloro o bromo o ungruponitro o alquilo C1-5, R4 es un átomo de hidrógeno o un grupo alquilo C1-5, bencilo o fenilo, y R5 es un átomo de hidrógeno o un grupo hidroxi o alcanoiloxi que tiene hasta 5 átomos de carbono, y en el cual la fórmula general (1) abarca una forma (+), una forma (-) y una forma (+-) o una de sus sales farmacológicamente aceptables.
ES91911488T 1990-06-05 1991-06-05 Derivado de indol. Expired - Lifetime ES2098357T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14817990 1990-06-05
JP33545890 1990-11-29

Publications (1)

Publication Number Publication Date
ES2098357T3 true ES2098357T3 (es) 1997-05-01

Family

ID=26478480

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91911488T Expired - Lifetime ES2098357T3 (es) 1990-06-05 1991-06-05 Derivado de indol.

Country Status (9)

Country Link
US (2) US5244904A (es)
EP (2) EP0485636B1 (es)
JP (1) JP3180344B2 (es)
KR (1) KR950002885B1 (es)
CA (2) CA2224047A1 (es)
DE (1) DE69125099T2 (es)
ES (1) ES2098357T3 (es)
FI (1) FI920480A7 (es)
WO (1) WO1991018901A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2112744A1 (en) * 1991-07-05 1993-01-21 Vittorrio Vecchietti Hydroisoquinoline derivatives
FR2697850B1 (fr) 1992-11-10 1994-12-02 Univ Pasteur Nouveaux polypeptides ayant une activité de récepteur opioïde, acides nucléiques codant pour ces polypeptides et utilisations.
US5464841A (en) * 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) * 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
DE69602248T4 (de) * 1995-07-20 2000-10-26 Toray Industries, Inc. 4a-aryldecahydroisochinolin-verbindungen und ihre medizinische verwendungen
US5994327A (en) * 1995-11-17 1999-11-30 Astra Ab Process for the preparation of morphinans
US7232829B2 (en) * 2001-04-06 2007-06-19 Regents Of The University Of Minnesota Therapeutic compounds and methods
EP1517689A2 (en) * 2002-01-25 2005-03-30 Regents Of The University Of Minnesota Selective analgesic agents
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
SG11202007422QA (en) 2018-02-05 2020-09-29 Alkermes Inc Compounds for the treatment of pain
US20230146716A1 (en) 2021-10-14 2023-05-11 Biosense Webster (Israel) Ltd. Digital twin of atria for atrial fibrillation patients
US20240020926A1 (en) 2022-07-14 2024-01-18 Biosense Webster (Israel) Ltd. Correcting a segmentation curve in an anatomical model
US20240335169A1 (en) 2023-03-31 2024-10-10 Biosense Webster (Israel) Ltd. Methods and systems for displaying quality profiles points in an electro-anatomical map
US20240386888A1 (en) 2023-05-18 2024-11-21 Biosense Webster (Israel) Ltd. Method and system for voice activated display in electrophysiology procedures
US20250000573A1 (en) 2023-06-21 2025-01-02 Biosense Webster (Israel) Ltd. Method and system for calculating and utilizing pfa ablation index
US20240428781A1 (en) 2023-06-21 2024-12-26 Biosense Webster (Israel) Ltd. Apparatus and system for improving troubleshooting in medical systems
US20250000574A1 (en) 2023-06-29 2025-01-02 Biosense Webster (Israel) Ltd. System and method for shape tracking of intrabody object subject to deformation
US20250025089A1 (en) 2023-07-21 2025-01-23 Biosense Webster (Israel) Ltd. Estimation and visualization of electroanatomical (ea) analysis quality of an ea map
US12543995B2 (en) 2023-07-28 2026-02-10 Biosense Webster (Israel) Ltd. Methods and systems for shaving an anatomical map
US20250134574A1 (en) 2023-10-25 2025-05-01 Biosense Webster (Israel) Ltd. Graphically encoded ablation tags according to regions of anatomy
US20250160960A1 (en) 2023-11-17 2025-05-22 Biosense Webster (Israel) Ltd. Map deformation for anatomical mapping
US20250169765A1 (en) 2023-11-29 2025-05-29 Biosense Webster (Israel) Ltd. Respiration compensation for mapping
US20250176932A1 (en) 2023-11-30 2025-06-05 Biosense Webster (Israel) Ltd. Guided entrance to epicardial sack with transthoracic ultrasound
US20250221649A1 (en) 2024-01-09 2025-07-10 Biosense Webster (Israel) Ltd. Impedance based tracking of catheter location in relation to a cavity wall
CN120381331A (zh) 2024-01-29 2025-07-29 伯恩森斯韦伯斯特(以色列)有限责任公司 使用符号距离函数来可视化脉冲场消融（pfa）标签
US20250311958A1 (en) 2024-04-09 2025-10-09 Biosense Webster (Israel) Ltd. Mapping a cavity
US20250352261A1 (en) 2024-05-14 2025-11-20 Biosense Webster (Israel) Ltd. Ablation location prediction over anatomical maps
IL321747A (en) 2024-06-27 2026-01-01 Biosense Webster Israel Ltd Systems and methods for creating an ecg depth and radial lens
US20260013939A1 (en) 2024-07-09 2026-01-15 Biosense Webster (Israel) Ltd. Methods and systems for identifying conduction flow paths in anatomical maps
EP4678092A1 (en) 2024-07-11 2026-01-14 Biosense Webster (Israel) Ltd. Methods, systems, and gui for enhanced real-time visual feedback of intraluminal catheter engagement
US20260013750A1 (en) 2024-07-15 2026-01-15 Biosense Webster (Israel) Ltd. Magnetic based sheath detection
US20260026727A1 (en) 2024-07-23 2026-01-29 Biosense Webster (Israel) Ltd. System and method for far-field voltage mapping for scar severity estimation
US20260060761A1 (en) 2024-08-28 2026-03-05 Biosense Webster (Israel) Ltd. Ablation tag connector lines and ablation count
US20260090756A1 (en) 2024-10-01 2026-04-02 Biosense Webster (Israel) Ltd. Identification of sites corresponding to suspected atrial fibrillation triggers based on correlation of signals from multiple electrodes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2351599A1 (de) * 1972-07-20 1974-01-31 Du Pont 4a-aryl-trans-decahydrochinoline und verfahren zu ihrer herstellung
US4419517A (en) 1973-06-01 1983-12-06 E. I. Du Pont De Nemours & Co. 4a-Aryl-trans-decahydroisoquinolines
US3933827A (en) * 1974-10-29 1976-01-20 Hoffmann-La Roche Inc. 9-Acyloxy-5,11-dimethyl-6H-pyrido[4,3-B]carbazoles
US4310667A (en) * 1976-04-22 1982-01-12 Agence Nationale De Valorisation De La Recherche (Anvar) 2-N Quaternary ammonium salt derivatives of 9-hydroxy ellipticine
US4189583A (en) 1978-04-26 1980-02-19 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 4A-aryl-decahydroisoquinolines
FR2436786A1 (fr) * 1978-09-21 1980-04-18 Anvar Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments
US4816586A (en) 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
JP2985322B2 (ja) 1991-03-01 1999-11-29 東レ株式会社 イソキノリン誘導体およびその医薬用途

Also Published As

Publication number Publication date
KR920702360A (ko) 1992-09-03
DE69125099D1 (de) 1997-04-17
KR950002885B1 (ko) 1995-03-28
CA2064853A1 (en) 1991-12-06
US5244904A (en) 1993-09-14
EP0485636B1 (en) 1997-03-12
CA2064853C (en) 1999-08-24
FI920480A0 (fi) 1992-02-04
FI920480A7 (fi) 1992-02-04
WO1991018901A1 (en) 1991-12-12
CA2224047A1 (en) 1991-12-06
EP0735026A1 (en) 1996-10-02
US5539119A (en) 1996-07-23
EP0485636A4 (en) 1992-11-19
JP3180344B2 (ja) 2001-06-25
DE69125099T2 (de) 1997-06-19
EP0485636A1 (en) 1992-05-20

Similar Documents

Publication Publication Date Title
ES2098357T3 (es) Derivado de indol.
FI960751A0 (fi) Substituoidut atsaindolylideeniyhdisteet ja menetelmä niiden valmistamiseksi
FR2512024B1 (es)
PE2799A1 (es) Lactamas e imidas heterociclicas de aralquilo y aralquilideno
EA200101194A1 (ru) Производные 4,5,6,7-тетрагидроиндазола в качестве противоопухолевых средств
ATE21699T1 (de) Verfahren zur herstellung von 2-penemverbindungen.
MY100740A (en) Spiro-substituted glutaramide diuretic agents.
AR005462A1 (es) Un proceso para preparar ciertos ciclohexapeptidos y compuestos obtenidos mediante dicho procedimiento.
DE3268225D1 (de) 9-(2-(3-indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
CO4990965A1 (es) Derivados de 1,3,8-triazaspiro(4,5)decan-4-ona to que los contiene y un proceso para la preparacion de es- tos derivados
ES8507090A1 (es) Procedimiento para la obtencion de nuevas 1, 5-benzotiacepinas
AR240823A2 (es) Procedimiento de preparacion de una cefalosporina
SE7903450L (sv) Nya substituerade 1,3-diaryl-2-imino-imidazolidiner och -2-imino-hexahydro-pyrimidiner och sett for framstellning derav
DK0383686T3 (da) Carboxyalkylethere af 2-amino-7-hydroxytetralin samt fremgangsmåde til fremstilling deraf
AR004675A1 (es) Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas.
AU562182B2 (en) Bicyclo(4,2,0)1,3,5-octatriene derivatives
ECSP941143A (es) Indoles
ES453787A1 (es) Un procedimiento para la preparacion de compuestos de nido- lina.
AR017500A1 (es) Derivados de naftilpiperacin-ftalacinonas
ATE108769T1 (de) Verfahren zur herstellung von phenylsulfonamiden.
ES2059261A1 (es) Alquil-bisacilfosfinoxidos.
ES2113382T3 (es) Derivados de azetidinona y procedimiento para producir derivados de azetidinona y cefalosporina.
CO4970778A1 (es) Nuevos compuestos
AR241163A2 (es) Procedimiento para obtener derivados de chartreusina y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 485636

Country of ref document: ES